Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child
Virus Research, Volume 127, No. 1, Year 2007
Notification
URL copied to clipboard!
Description
A type 2 vaccine-derived poliovirus (VDPV), differing from Sabin 2 at 2.5% (22/903) of VP1 nucleotide (nt) positions, was isolated from an incompletely immunized 21-month-old Nigerian child who developed acute flaccid paralysis in 2002. Sequences upstream of nt position 620 (within the 5′-untranslated region [5′-UTR]) and downstream of nt position 5840 (in the 3Cpro region) were derived from species C enteroviruses unrelated to the oral poliovirus vaccine (OPV) strains. The two substitutions associated with the attenuated phenotype had either recombined out (A481 → G in the 5′-UTR) or reverted (Ile143 → Thr in VP1). The VDPV isolate had lost the temperature sensitive phenotype of Sabin 2 and it was antigenically distinct from the parental OPV strain, having amino acid substitutions in or near neutralizing antigenic sites 1 and 3. The date of the initiating OPV dose, calculated from the number of synonymous substitutions in the capsid region, was estimated to be ∼16 to 18 months before onset of paralysis, a finding inconsistent with the most recent mass OPV campaign (conducted 12 days before onset of paralysis) as being the source of infection. Although no related type 2 VDPVs were detected in Nigeria or elsewhere, the VDPV was found in an area where conditions favor VDPV emergence and spread. © 2007 Elsevier B.V. All rights reserved.
Authors & Co-Authors
Adu, Festus Doyin
Nigeria, Ibadan
College of Medicine, University of Ibadan
Iber, Jane C.
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Bukbuk, David Nadeba
Nigeria, Maiduguri
University of Maiduguri
Gumede, Nicksy
South Africa, Johannesburg
National Institute for Communicable Diseases
Yang, Su Ju
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Jorba, Jaume C.
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Campagnoli, Ray
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Sule, Waidi Folorunso
Nigeria, Ibadan
College of Medicine, University of Ibadan
Yang, Chen Fu
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Burns, Cara Carthel
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Pallansch, Mark A.
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Harry, Tekena O.
Nigeria, Maiduguri
University of Maiduguri
Kew, Olen M.
United States, Atlanta
National Center for Immunization and Respiratory Diseases
Statistics
Citations: 65
Authors: 13
Affiliations: 4
Identifiers
Doi:
10.1016/j.virusres.2007.03.009
ISSN:
01681702
Research Areas
Health System And Policy
Maternal And Child Health
Study Locations
Nigeria